The Sexually Transmitted Infections (STI) podcast offers the latest updates on the transmission, prevention, diagnosis and treatment of STIs and HIV. Each episode features in-depth interviews with renowned authors and leading experts in the field, delving into the latest research.
Stay ahead in your field by tuning into our expert discussions and accessing cutting-edge content.
Subscribe to the STI podcast and visit the STI journal website - sti.bmj.com - to stay up to date.
We have been following emerging data on the efficacy of clinical vaccine trials against Neisseria gonorrhoeae, a ubiquitous sexually transmitted bacteria that can cause localised and systemic disease if left untreated. It can also be transmitted to neonates during birthing. Worldwide there has been a steady rise of gonorrhoea incidence and antibiotic resistance. In 2024 UK's Joint Committee on Vaccination and Immunisation recommended the off-label use of 4CMenB vaccine for the prevention of gonorrhoea infection in persons at high risk. Here we present the recent findings of the GoGoVax trial which presented at CROI 2026.
Links:
Revisiting gonorrhoea prevention in the era of resistance and biomedical interventions
Multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against Neisseria gonorrhoeae infection in men who have sex with men: the GoGoVax study protocol
GoGoVax | Kirby Institute
GoGoVax dispels hopes for gonorrhoea vaccination
Participants:
Host: Ass Prof/Dr Fabiola Martin, Canberra Sexual Health Centre and Australian National University, Canberra, AustraliaProf Kate Seib, Principal Research Leader and NHMRC Leadership Fellow, Institute for Biomedicine and Glycomics, Griffith University in Australia
14 Aug 2026
Escalating HIV Epidemic in Fiji
Fiji has been reporting a significant rise in the incidence of Human immunodeficiency (HIV) and hepatitis C virus (HCV) over the last 3 years. Health officials estimate that about 9,000 people are living with HIV in Fiji today, nearly 1% of the population. A startling 2,016 new cases of HIV alone were reported in 2025, compared to 1,583 cases in 2024. Among people starting HIV treatment in 2024, 48% were people who inject drugs, highlighting the disproportionate impact on this group, and unsafe injecting drug use being the major driver of transmission, exposing urgent gaps in access to prevention and stigma-free care.
In addition, an estimated 59 infants were born with HIV in 2025, up from 31 in 2024, demonstrating the spread of HIV through sexual transmission and from birthing parent to child. There are limited epidemiological data available on HCV in Fiji but it's sharp rise has also been observed.
Links:
Fiji strengthens its HIV response through evidence-based harm reduction
Fiji’s HIV Epidemic Escalates
Strengthening Fiji’s HIV response through shared expertise and regional collaboration
Participants:
Host: Ass Prof/Dr Fabiola Martin, Canberra Sexual Health Centre and Australian National University, Canberra, Australia
Dr Jason Mitchell, Lead of the SRH and HIV Unit at Ministry of Health and Medical Services and Chairperson of the National HIV Outbreak and Cluster Response Taskforce in Fiji
22 May 2026
Anal Intraepithelial Neoplasia in People Assigned Female at Birth
The experience of treating and/or losing a patient to anal cancer is deeply upsetting. Therefore, the early detection and treatment of precursors are of utmost importance to patients and clinicians. People with HIV have a higher prevalence and incidence of Human Papilloma Virus infection, an oncogenic virus, which may cause intraepithelial neoplasia, the precursor of squamous cell carcinomas in the anal canal. Though encouraging progress has been made to support gay and bisexual men and transgender women with HIV from developing anal cancer, research and health policies do not offer specific prevention strategies against anal cancer in people assigned female at birth. In this podcast Dr Tamzin Cuming outlines progress made so far and areas of research and health care that need further attention.
Links:
https://iansoc.org/Board-of-Directors
Host: Ass. Prof./Dr. Fabiola Martin, BMJ STI Podcast Editor, Sexual Health and HIV Specialist, Clinical Associate Professor, Australian National University, Canberra, Australia
Guest: Dr Tamzin Cuming, Consultant Colorectal Surgeon, President of International Anal Neoplasia Society, Homerton Hospital, in London, UK
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
4.3 / 5
3 ratings
Spotify
4.0 / 5
4 ratings
Podcast Authority Score: 34 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
35
Social presence
0
YouTube
0
Engagement
81
Contact STI Podcast
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of STI Podcast?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
